Bassam Roukoz, MD
Interventional Cardiology · Festus, MONPI 1396744439
Payments from drug & device makers
Across 406 payments — averaging $26.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
- Abiomed$889
- Abbott$806
- Boston Scientific$747
- Johnson & Johnson$721
- plus $6K from 29 others
What the payments were for
- Consulting fees$3503%
- Food & beverage$10,29896%
- Education$1231%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 22 | $1,054 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 68 | $1,009 |
| Abiomed | 8 | $889 |
| Abbott | 29 | $806 |
| Boston Scientific | 36 | $747 |
| Johnson & Johnson | 45 | $721 |
| Boehringer Ingelheim | 15 | $676 |
| Shockwave Medical, Inc | 21 | $658 |
| Amgen | 31 | $571 |
| E.r. Squibb & Sons, L.L.C. | 23 | $431 |
| Novartis | 26 | $430 |
| AstraZeneca | 5 | $404 |
| Penumbra, Inc. | 3 | $324 |
| Sanofi-aventis U.S. LLC | 9 | $301 |
| Philips North America LLC | 4 | $260 |
| Pfizer | 14 | $243 |
| Cardiovascular Systems Inc. | 4 | $197 |
| Actelion Pharmaceuticals US, Inc. | 8 | $187 |
| Cordis US CORP. | 1 | $132 |
| Biotronik Inc. | 6 | $112 |
| Intuitive Surgical | 1 | $75 |
| Amarin Pharma, Inc. | 4 | $61 |
| Edwards Lifesciences | 2 | $59 |
| Inari Medical, Inc. | 2 | $58 |
| Regeneron Healthcare Solutions, Inc. | 3 | $54 |
| Scpharmaceuticals Inc. | 3 | $51 |
| Cook Medical LLC | 2 | $45 |
| ZOLL Circulation Inc | 2 | $38 |
| Esperion Therapeutics, Inc. | 2 | $35 |
| Angiodynamics, Inc. | 1 | $33 |
| Merck | 2 | $31 |
| Bayer | 1 | $24 |
| Lexicon Pharmaceuticals, Inc. | 1 | $24 |
| Teleflex LLC | 1 | $16 |
| Irhythm Technologies, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$831
- JARDIANCE$330
- Resolute$250
- BRILINTA$245
- Indigo System$237
- AMPLATZER$167
- AVVIGO Guidance System$148
- MULTAQ$137
- PRECISE PRO RX$132
- Coronary Orbital Atherectomy System$125
- Lasers$125
- FARXIGA$125
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$124
- LINQ II$123
- Mitra Clip system$100
How this compares
$10,770 in reported general payments places this provider in the 45th percentile of 182 interventional cardiology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 566 | $521,873 |
| XareltoRivaroxaban | 191 | $182,657 |
| EntrestoSacubitril/Valsartan | 154 | $143,511 |
| JardianceEmpagliflozin | 55 | $68,355 |
| BrilintaTicagrelor | 55 | $38,999 |
| Repatha SureclickEvolocumab | 46 | $31,706 |
| MultaqDronedarone Hcl | 11 | $14,716 |
| Praluent PenAlirocumab | 13 | $11,182 |
| Metoprolol Succinate | 986 | $9,891 |
| Ranolazine ErRanolazine | 74 | $6,852 |
| Atorvastatin Calcium | 715 | $6,104 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 601 | $6,069 |
| ClopidogrelClopidogrel Bisulfate | 622 | $5,605 |
| Amiodarone Hcl | 185 | $5,499 |
| Losartan Potassium | 629 | $5,175 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $243 | $521,873566 claims |
| Johnson & JohnsonXarelto | $721 | $182,657191 claims |
| NovartisEntresto | $430 | $143,511154 claims |
| Boehringer IngelheimJardiance | $676 | $68,35555 claims |
| AstraZenecaBrilinta | $404 | $38,99955 claims |
| Sanofi-aventis U.S. LLCMultaq | $301 | $14,71611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 182 interventional cardiology providers in Missouri.
Other interventional cardiology in Festus
- Harvey SerotaSaint Louis$7.1M
- Adnan ChhatriwallaKansas City$3.6M
- Gil VardiSaint Louis$2M
- Alan ZajariasSaint Louis$1.6M
- James GranthamKansas City$1.6M
- Anish ThomasSaint Louis$1.5M
- Richard BachSaint Louis$1.5M
- Joshua StolkerWashington$1.2M
- John LasalaSaint Louis$995K
- Jasvindar SinghSaint Louis$993K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.